CJC-1295 with DAC (Drug Affinity Complex) is a synthetic research peptide designed as a long-acting growth hormone–releasing hormone (GHRH) analog. The addition of DAC extends its half-life compared to the non-DAC version, allowing researchers to explore sustained effects in laboratory models. CJC-1295 with DAC has become a key subject of interest in studies related to growth hormone release, metabolic regulation, and recovery processes.

Area of Interest

Research into CJC-1295 with DAC has highlighted several areas of scientific exploration:

• Growth Hormone Secretion: Studied for its ability to stimulate pulsatile GH release over an extended timeframe compared to shorter-acting GHRH analogs.
• Metabolic Studies: Explored for potential roles in glucose metabolism, lipid regulation, and body composition in preclinical models.
• Cellular Repair: Investigated for possible contributions to tissue recovery and protein synthesis pathways.
• Comparative Pharmacology: Provides an important contrast to CJC-1295 without DAC, enabling researchers to evaluate the effects of prolonged half-life in controlled studies.

Together, these areas make CJC-1295 with DAC a promising candidate for laboratory investigation where sustained GHRH activity is desired.

Technical Information

• Chemical Name: CJC-1295 with Drug Affinity Complex
• Synonyms: DAC-GRF(1-29), Modified GRF(1-29) with DAC
• Molecular Formula: C₁₅₂H₂₅₂N₄₄O₄₂
• Molecular Weight: ~3368 g/mol
• Sequence (Amino Acid): Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-Gln-Gln-Gly-Glu
• CAS Number: 863288-34-0
• Peptide Classification: Synthetic GHRH analog with half-life extending modification (DAC)

Storage Guidelines

• Lyophilized peptide is stable at room temperature for short periods.
• For long-term storage, keep at −20°C or below.
• Once reconstituted, store at 2–8 °C. Effective use depends on the solution used.
  

Solubility

CJC-1295 with DAC is soluble in sterile water, acetic acid, or aqueous buffers depending on formulation.

References

• Teichman, S. L., Neale, A., Lawrence, B., Gagnon, C., et al. (2006). “Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.” Journal of Clinical Endocrinology & Metabolism, 91(3), 799–805. https://doi.org/10.1210/jc.2005-1536
• Teichman, S. L., et al. (2004). “CJC-1295, a long-acting growth hormone–releasing hormone analog: results of a phase I study.” Journal of Clinical Endocrinology & Metabolism, 89(11), 5286–5292. https://doi.org/10.1210/jc.2004-0604

Certificate of Analysis (COA): Available here